Cellomatics immuno-oncology article published in Drug Discovery World

Cellomatics Founder & CEO Dr Shailendra Singh provides his expert opinion on the evolution of assays for immuno-oncology research in an article featured in the Winter 2022/23 publication of Drug Discovery World – a multi-platform global voice for the drug discovery community.

The article, titled ‘The evolution of assays for immuno-oncology research’ looks at the history of immuno-oncology, the rising demand in the assay market, and how the bespoke and customised approach can be used to further drug development.

View the Drug Discovery World article here.

Cellomatics is a preclinical immuno-oncology CRO offering expertise in robust and reproducible immuno-oncology related assays.

Find out more about our service offering here.

Request a consultation with Cellomatics Biosciences today

Our experienced team of in vitro laboratory scientists will work with you to understand your project and provide a bespoke project plan with a professional, flexible service and a fast turnaround time.

To request a consultation where we can discuss your exact requirements, please contact Cellomatics Biosciences.